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ABSTRACT 
 
 
Background 
Methadone is widely used to treat opiate addiction, in 
particular heroin. Proper administration via drug 
optimisation is the only way to achieve net clinical 
outcomes.  
 
Aims 
This is an observational cross-sectional study, sought to 
observe the clinical response to a methadone maintenance 
therapy (MMT) program.  
 
Methods  
Setting: Four treatment clinics in Kuala Lumpur, Malaysia.  
Patients and methods: One-hundred and twenty-two 
methadone patients. Their demographic characteristics, 
medical history, methadone doses, duration in the program, 
and compliance rates were recorded.  
Main outcome measures: The opiate withdrawal scale was 
used to assess the severity of withdrawal symptoms.  
 
Results  
The mean methadone dose was 50mg (range, 20–160mg). 
The minimum recorded duration in the MMT program was 
three months, the maximum was 40 months, and the mean 
was seven months. 90 per cent of the patients were 
addicted to multiple substances; of those, 70 per cent were 
addicted to three or more substances. Many patients 
reported cravings and seeking behaviours while on 
methadone. 
 
Conclusion 
Gradual increments in methadone doses are relatively safe, 
but patients should be monitored daily. Doses should be 
increased to control withdrawal symptoms. Despite optimal 
dosing, cravings and drug-seeking behaviours may not be 
controlled in some patients, and an alternative to 
methadone may be an option. 
 
Key Words 
Methadone, psychological dependence, detoxification, 
hypertension 
 
What this study adds:  
1. What is known about this subject?  
Methadone has been a good choice for opiate addiction 
with a reasonable safety profile especially in low doses. High 
doses may control addiction in a better way, with higher 
incidence of cardiac events.  
 
2. What new information is offered in this study? 
Although many patients have been optimized on 
methadone, seeking and craving might not disappear in full. 
Thus, this could be a sign for methadone failure, regardless 
of the positive control of withdrawal symptoms.  
 
3. What are the implications for research, policy, or 
practice?  
Monitoring seeking and craving alongside other withdrawal 
symptoms is very crucial in methadone therapy. 
Investigating the plasma level once the patient is 
therapeutic is judicious. Once seeking is evident, change to 
another alternative.  
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Background 
Addiction and substance abuse are a worldwide problem, 
and Malaysia is no exception. Opiate addiction is expected 
to affect nearly 1.3 per cent of adults in Malaysia.
1
 In 
addition to aggressive criminal activities, HIV risk may reach 
as much as 15 per cent in people who inject drugs.
2
 Thus, 
the establishment of methadone maintenance therapy 
(MMT) was an essential step in controlling opiate use and 
reducing HIV transmission.
3,4
 
  
MMT has been widely used in Malaysia to treat opiate 
addiction and reduce its associated risks.
5-7
 MMT helps to 
reduce the severity of withdrawal symptoms and gradually 
eliminate physical and psychological dependence.
8
 
Numerous countries have also been using this approach 
successfully, including the USA, the UK, Canada, 
Switzerland, the Netherlands, Germany, Italy, Australia, 
New Zealand, Bangladesh, Thailand and many others 
worldwide. The majority of those consider MMT a part of 
their national health program.
9,10  
 
At MMT clinics, addiction to opiates must be established 
clinically and historically, and the list of substances to which 
a patient is addicted must be enumerated as well. Once 
confirmed, the starting MMT dose depends on the type of 
program and the purity of heroin in that area. Overdosing 
on methadone can be fatal, while a too-low dose may lead 
to opiate withdrawal.
5,8,11-13
 Accordingly, the initial dose 
should range between 10–30mg. If the patient’s tolerance 
to opiates is very high, 25–40mg would be an appropriate 
dose; low dosing should be used if the tolerance is 
unknown. Patients should be kept under surveillance for 2–
4 hours, in case a dose increase is warranted. After that, 
patients should be seen daily during the first week to re-
assess the dosing scheme. Dosing can be increased by 5–
10mg, but not by more than 20mg weekly. For long-term 
detoxification, the net dose can reach 60–120mg by the 
same incremental fashion.
1,14,15
 It has been reported that 
low doses (40mg) are equivalent to high doses (80mg) with 
regard to opiate abstinence symptoms and cravings.
16–18
  
 
The MMT in Malaysia is run in the form of out-patient clinics 
and counselling, either in general practice clinics or 
hospitals. Patients are supervised on a daily basis for several 
months before being prescribed take-home methadone 
doses. Without evidence of compliance, patients are not 
allowed to take any doses back to their homes.
11–13
 
Advocates of the harm reduction approach of methadone 
recognise that full abstinence may not be reached in every 
case, but the approach aims instead to improve the health 
and social life of the addicts while on treatment, and to 
prevent the transmission of HIV and other dangerous 
infectious diseases.
16,19-21
  
 
Aims 
We sought to observe the clinical benefits of the MMT 
program, which may help to reduce the severity of 
withdrawal symptoms and help patients to overcome opiate 
addiction. 
 
Method 
This study had an observational cross-sectional design, and 
was approved by the ethics committee of Malaya University 
Hospital. Patients were invited to participate in this study in 
four clinics in Kuala Lumpur. The patients were heroin 
addicts who had been visiting the clinics daily for MMT for 
at least three months. Upon accepting, compliance to 
therapy was assessed based on the number of missed 
treatment days.
22
 Given the nature of the program, this 
method is simple to use and well-validated: 
 
Compliance % = (missed days for this month/30) × 100 
 
If compliance exceeded 80 per cent, patients were eligible 
to participate. Patients were excluded if they were: 
 
1. Not stable on methadone.  
2. Less than 80 per cent compliant.  
3. Not willing to sign the written informed consent 
form.  
 
If compliance exceeded 80 per cent, the study was 
explained to the patients, who were required to read the 
information sheet carefully and free to ask questions. Upon 
understanding and accepting the policy and procedure, they 
all were required to sign informed consent forms. Their 
demographic information and relevant medical and 
substance abuse history were recorded. Subjective and 
objective measurements for the Clinical Opiate Withdrawal 
Scale (COWS) and the Objective Opiate Withdrawal Scale 
(OOWS) were recorded as well.
23,24
 Due to the nature of the 
program, the names of the patients and clinics were kept 
confidential.  
 
All descriptive data were summarised in Excel® (Microsoft 
Corporation, Redmond, WA, USA). Minitab® version 17 
(Minitab Inc., State College, PA, USA) was used to analyse 
the data and generate all statistical calculations. The level of 
significance (α) was set at 0.05. The data were all checked 
for normality before appropriate statistical tests were 
selected. Spearman's rho was used for correlation and 
ANOVA for dose comparison among the clinics. 
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Results 
Demographics 
Table 1 displays the means of subjects’ demographic 
characteristics. The vast majority of our subjects were male 
(120); there were only two female subjects in the study. The 
majority were Malay (90 per cent), followed by six per cent 
Chinese, three per cent Indian and one per cent Pakistani. 
The maximum reported dose was 160mg, and the maximum 
MMT duration was 40 months. Both high values were 
reported for one patient only. The minimum reported dose 
was 20mg, and the minimum duration was three months. 
The median methadone dose was 50mg, and the median for 
duration was 7 months. All subjects continued MMT after 
the completion of the study. The most commonly abused 
substances were amphetamines, amphetamine-type 
stimulants (ATS), and Ganja (Figure 1).  
 
Table 2 displays the medical conditions reported by the 
patients in this study. Three patients had hypertension, 
although only one of them was actively treated with 
amlodipine. Four patients had asthma, and all were treated 
for acute situations with Ventolin® and corticosteroid 
inhalers. Two patients were diagnosed with depression and 
were prescribed the psychotropics lorazepam, fluvoxamine, 
haloperidol and benzhexol. A few others reported current 
use of the antibiotics Bactrim® and Augmentin® and the 
pain reliever paracetamol. Eight patients took 
multivitamins, five took protein supplements, three used 
herbal remedies and one reported taking calcium 
supplements. 
 
Opiate abstinence symptoms  
The most reported symptoms were yawning, sweating, 
tearing, restless sleep, muscle twitching, flushes, irritability, 
anorexia, insomnia, restlessness, low-grade fever, 
abdominal cramps, diarrhoea, weight loss and general 
weakness. The opiate abstinence scores were computed 
accordingly. Figures 2-4 show a clear variability between the 
four clinics. Subjects in clinic 4 had the highest craving rates 
(Figure 2). Drug-seeking behaviours were highest in clinic 3 
(Figure 3). In contrast, a large number of subjects presented 
with no COWS in clinics 1 and 2 (Figure 4). 
 
ANOVA calculations revealed a significant difference in 
mean dosing between the four clinics: 60, 90, 72 and 40mg 
(p=0.0001). Dosing in clinic 1 differed least from the mean 
for all clinics. The mean for clinic 2 (90mg) was the highest. 
In terms of the COWS, no significant difference was found 
between the clinics (p=0.38). A moderate correlation was 
found between the size of the dose and the compliance 
(Spearman's r=0.6). However, only a weak negative 
correlation was detected between the dose and the opiate 
abstinence score (Spearman's r=−0.1). Likewise, only a weak 
negative correlation was detected between compliance and 
the opiate abstinence score (Spearman's r=−0.1) 
 
Discussion 
This study described the clinical benefits of a cohort at the 
MMT program in Malaysia. The demographics and types of 
substances used are all similar to what has been described 
by the National Anti-Drugs Agency (AADK, 
www.adk.gov.my). 
 
The primary objective of MMT is to eliminate withdrawal 
symptoms. It has been reported in the literature that 
methadone doses of 80–120mg can relieve narcotic 
cravings, suppress the opiate abstinence syndrome for 24–
36 hours, block the effects of administered heroin, and help 
develop tolerance to euphoria. The exact dose would 
depend mainly on clinical endpoints.
26,27
 Increasing the 
methadone dose gradually helps to avert any potential fatal 
adverse events and to ameliorate the withdrawal 
symptoms. Nonetheless, the complexities involved in 
methadone dosing can lead to either overdosing or 
withdrawal symptoms.
6,7
 
 
Very high doses, however, must be used cautiously. MMT’s 
medical safety has been monitored since 1964, and it is 
considered a safe and non-toxic therapy with only a few 
transient, treatable adverse effects.
5,28
 Serious adverse 
events are rarely reported in MMT programs. However, 
mortality from overdosing has been reported numerous 
times.
29,30
 Therefore, MMT inclusion criteria are very strict 
in many countries, and include a consideration of factors 
such as age, supervision, addiction history, compliance and 
strict follow-up. Several risk factors have been suggested to 
increase methadone mortality, including overdosing, lack of 
compliance, benzodiazepine and antipsychotics use, alcohol 
abuse, heart failure and mood disorders.
31
 Our study and 
other Malaysian studies reported no serious adverse drug 
reactions in subjects if the recruitment and dose 
optimisation processes were carefully designed.
3,4,6,7
 
  
Most of our subjects seemed clinically stable and satisfied 
with doses of 50–70mg. Some of them, however, presented 
with some withdrawal symptoms, which may warrant 
higher doses for better management. The symptoms 
reported varied among the clinics and patients. Control of 
cravings and seeking behaviours cannot be achieved in all 
patients; changing from methadone to another alternative 
could be a good strategy if problems persist.
29
 The most 
common symptoms among our patients were heroin 
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seeking, heroin craving, anxiety, yawning, restless sleep, 
flushes, irritability, insomnia, restlessness, low-grade fever, 
abdominal cramps, diarrhoea and general weakness. For the 
most part, these symptoms are an integral part of opiate 
withdrawal. Therefore, dosing can be increased by 5–10mg, 
but by no more than 20mg weekly. For long-term 
detoxification, the net dose can reach 60–120mg by the 
same incremental scale.
14,15
 Heroin craving and seeking 
behaviours among long-term MMT patients has been 
reported numerous times.
17,18,32,33
 A relationship between 
methadone levels and craving patterns has been found only 
for subjects who were in the therapeutic range of 
methadone. In contrast, when methadone doses were sub- 
or supra-therapeutic, no relationship was identified and 
patterns were inconsistent.
14,17
 Unfortunately, we could find 
no recent studies on this phenomenon, and this study did 
not investigate methadone plasma levels. A large 
percentage of our patients reported no withdrawal 
symptoms overall, indicating a full abstinence. This study 
found that the percentage of cravings and seeking 
behaviours reported were lower with a higher-dose 
regimen. Further, we reported a very weak negative 
correlation between dose and the opiate abstinence score, 
and a very weak negative correlation between compliance 
and the opiate abstinence score.  
 
Psychosocial and psychotherapeutic risks are independent 
risk factors for the success of the treatment.
33–35
 Moreover, 
the number of substances to which a patient is addicted 
may contribute to the cumulative impact. Numerous recent 
studies have shown a strong inverse correlation between 
the number of illicit substances and the size of the required 
MMT dose. Furthermore, when the dosage was titrated to 
clear the subjective and objective measures of withdrawal 
symptoms, not according to any ceiling, the number of illicit 
substances was reduced drastically.
36
 This study, however, 
did not find any significant difference between the number 
of illicit substances and dosing. In addition, frequent use of 
amphetamine derivatives may be an indicator of sub-
optimal therapy.
37
 
 
This study is small in nature and patients were not followed 
up frequently. Thus, a larger study is required to assess the 
net clinical benefits with multiple follow up design.  
 
Conclusion 
Methadone seems to be a good choice for many patients to 
overcome opiate addiction. Close monitoring and gradual 
dose increments are recommended. Reducing cravings and 
drug-seeking behaviours should be the primary targets, and 
controlling them may not always be achieved with 
methadone. Patients treated with inadequate methadone 
doses may complement the methadone with illicit 
substances, masking the actual need for higher methadone 
doses. 
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Table 1: Means of subjects’ demographic characteristics 
 
Characteristic Mean (SD) 
Compliance (%) 90 (10) 
Dose (mg) 50 (20) 
Duration (months) 11 (7) 
Age (years)  38 (8) 
Body Mass Index 22 (6) 
 
Table 2: Baseline medical history and medication information 
 
Disease or disorder Number of patients 
Number of patients 
receiving active therapy 
Hepatitis C 3 1 
Hepatitis B 8 1 
HIV 5 2 
Co-infection: Hepatitis C and HIV 1 2 
Hypertension 3 1 
Asthma 4 4 
Depression 1 3 
Asthma and depression 1 1 
 
Figure 1: Most commonly abused substances 
 
 
Figure 2: Percentage of subjects experiencing drug cravings 
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Figure 3: Percentage of subjects displaying drug-seeking behaviours 
 
 
 
Figure 4: Percentage of subjects reporting no withdrawal symptoms 
 
 
 
 
 
